Few & Far Between

Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for conversations on the cutting edge - from clinical research and policymakers to rare disease advocates and industry leaders.

Latest Episodes

38

May 23, 2024 00:35:24
Episode Cover

Episode 41: Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health

"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help...

Listen

40

April 25, 2024 00:33:23
Episode Cover

Episode 40: Professor Justin Stebbing, Editor-in-Chief, Oncogene journal

"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the...

Listen

39

March 26, 2024 00:45:10
Episode Cover

Episode 39: Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center

"Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in real time, like...

Listen

38

February 22, 2024 00:38:27
Episode Cover

Episode 38: Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School

"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to...

Listen

37

January 24, 2024 00:41:31
Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche

Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche

"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...

Listen

36

December 05, 2023 00:51:43
Episode Cover

Episode 36: Zak Kohane, Department of Biomedical Informatics at Harvard Medical School

"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...

Listen
Next